Skip to content
Bored Studies
RecruitingPhase 4

ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)

Novartis Pharmaceuticals · NCT07448610

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 2–100 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 4
Target enrollment
36
US sites recruiting
1
Study start
August 27, 2026
Record last updated
September 18, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The primary purpose is to address critical evidence in the treatment landscape for Spinal Muscular Atrophy (SMA), specifically focusing on the intrathecal formulation of onasemnogene abeparvovec-brve (ITVISMA®). U.S. Pragmatic Multicenter Study (STREAM).

Being studied: Onasemnogene Abeparvovec-brve

Conditions: Spinal Muscular Atrophy

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria

A participant will be enrolled in STREAM only if all the following conditions are met:

  • The participant has a genetically confirmed diagnosis of SMA (biallelic SMN1 deletion or mutation).
  • He or she is ≥ 2 years of age on the day of the intrathecal injection.
  • The treating Investigator intends to administer within the current episode of care, a single dose of ITVISMA® (1.2 × 10¹⁴ vg) in routine U.S. practice after written informed consent obtained.
  • One of the following functional categories applies at screening:
  • independently ambulatory child/adolescent 2 - \<18 years; or
  • independently ambulatory adult (≥ 18 years).
  • non-ambulatory (includes walkers with assistance) adult > 18 years with entry level RULM at baseline
  • At least 1 year of pre-treatment medical history, including motor-function documentation, can be retrieved from the site electronic record.

Key Exclusion Criteria

A participant will be excluded if any of the following conditions apply:

  • Contraindication for lumbar puncture as determined by the investigator (e.g., spinal anatomy that precludes safe lumbar puncture)
  • An uncontrolled acute illness, active infection, febrile illness or acute medical condition, within 30 days prior to dosing
  • Inability to tolerate corticosteroids administered by mouth or gastrostomy tube
  • Current participation in another interventional clinical trial that would interfere with the objectives or endpoints of STREAM. Note: participation in observational cohort studies or non-interventional studies in which the participant does not receive treatment or undergo procedures which may compromise this study data integrity may be allowed following Sponsor approval
  • Planned relocation or any circumstance that is likely to prevent completion of the minimum 12-month follow-up.

Other protocol inclusion, exclusion criteria may apply.

Recruiting US locations

  • Columbia University Medical Center

    New York, NY 10032

    Site contact: Claudia Chiriboga

Study contacts (from the official record)

  • Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
  • Novartis Pharmaceuticals
ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular… (NCT07448610) | Bored Studies